Recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT) are at high risk for invasive mold infections (IMI). The goal of the study is to describe the incidence and outcome of IMI in patients after allo-HSCT in a large cohort of patients receiving anti-mold prophylaxis. We conducted a retrospective review of 988 consecutive adults who underwent allo-HSCT in our center from 2008 through 2014.
| INTRODUC TI ON
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment option for many malignant and non-malignant hematological diseases. While treatment-related mortality (TRM) remains a major concern of this procedure, mostly driven by infections and graft-versus-host disease (GVHD), several studies have shown a decrease in TRM in recent years due to a variety of factors.
1,2 One such factor is the improved management of invasive mold infections (IMI), including new diagnostic tools and active drugs both in the prophylactic and treatment settings. These improvements have led to an apparent decrease in the mortality of these infections. 3 The use of anti-mold prophylaxis in contemporary patients undergoing allo-HSCT has been evaluated in some clinical trials with strict inclusion criteria. [4] [5] [6] [7] However, there is a paucity of studies addressing this issue in large cohorts of "real-life" allo-HSCT patients.
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The goal of this study was to describe the incidence and outcome of IMI in a large contemporary cohort of allo-HSCT from a single center receiving anti-mold prophylaxis.
| ME THODS

| Patients and transplant procedure
All consecutive patients 18 years old or older who received their first allo-HSCT for hematological malignancies from January 2008
to December 2014 at Memorial Sloan Kettering Cancer Center (MSKCC) were included. Patients with hematological non-malignant diseases and solid tumors were excluded.
All stem cell sources, conditioning regimens and GVHD prophylactic strategies were included and have been previously described. [11] [12] [13] In brief, pre-transplant conditioning intensity varied according to patient age, comorbidities and previous therapy received, and could be either chemotherapy-based or in combination with total body irradiation. GVHD prophylaxis was calcineurin inhibitor-based in the majority of patients, except for patients receiving CD34+ selected grafts who did not receive any prophylactic immunosuppressive agents post-transplant. 
| Diagnosis of IMI and prophylaxis strategy
Invasive mold infections cases were identified through a systematic review of histopathology reports consistent with invasive mold in- ports. In our center, patients with persistent fever underwent thoracic CT-scan routinely. β-D-Glucan and Galactomannan were ordered at the discretion of the treating clinician and positive tests were followed.
The tests were routinely performed in allo-HSCT patients with neutropenic fever on broad-spectrum antibiotics, corticosteroid therapy and/ or active GVHD, as well as patients with pulmonary symptoms or find- Galactomannan were 80 pg/mL and index >0.5, respectively.
During the study period the standard of care for antifungal prophylaxis was micafungin 150 mg IV daily given from the start of conditioning to day +7 ± 3 days after HSCT and changed to voriconazole until day +75 to +100 after transplantation, initially IV and switched to PO when oral intake by the patient could be as- Calcineurin inhibitors and sirolimus doses were adjusted in patients switched to an azole as previously reported. 
| Endpoints, definitions and statistical analysis
The primary endpoint of the study was the cumulative incidence of IMI. Secondary endpoints included overall survival after IMI and description of IMI characteristics. Causes of death were established according to the Copelan algorithm. 17 Mold-related mortality was attributed to patients who died within 12 weeks from the time of IMI diagnosis in the absence of relapse of the hematological malignancy.
The cumulative incidence of IMI was estimated treating relapse and death in the absence of diagnosed IMI as competitive events.
Gray's test was used to compare IMI incidence by disease and of IMI after transplantation is low in patients receiving anti-mold prophylaxis with micafungin bridged to voriconazole, although these infections are associated with a higher risk of mortality.
K E Y W O R D S
allogeneic hematopoietic stem cell transplantation, antifungal, invasive fungal infection, molds treatment characteristics. Kaplan-Meier methods were used to estimate overall survival following IMI. All analyses were done by using R v3.1.2.
| RE SULTS
A total of 988 patients undergoing allo-HSCT during the study period were included. Patients' characteristics are summarized in Table 1 .
In brief, median age at HSCT was 54 (range Multiple myeloma 103 (10) 1 (5) 102 (11) Myelodisplastic syndrome 127 (13) 3 (14) 124 (13) Myeloproliferative neoplasm
Previous autologous transplant, n (%)
181 (18) 3 (14) 178 (18) Conditioning, n (%) Thirteen (59%) patients with IMI had received systemic corticosteroids within the 30 days prior to diagnosis, eleven for GVHD. Ten patients (45%) were not receiving the planned anti-mold prophylaxis at the time of IMI, due to azole-related hepatotoxicity (n = 7), drug allergy (n = 1), patient preference (n = 1) and unknown reason (n = 1).
Three patients were off prophylaxis as they were beyond day +100
and had no additional risk factors. The remaining 9 patients were receiving the planned anti-mold prophylaxis at the time of IMI diagnosis. Detailed clinical characteristics of patients with IMI are shown in Table S1 .
No risk factors for the development of IMI were identified, which may be due to the low IMI event rate. When analyzed by disease, there was a trend for a higher cumulative incidence of IMI at 
| D ISCUSS I ON
This study of a large contemporary cohort of HCT recipients at a major cancer center with a standardized anti-mold prophylactic strategy reports a low overall incidence of IMI and identifies some populations with a very low risk of developing these infections.
The cumulative incidence of IMI at 1 year reported in our single center study is somewhat lower than that reported in contemporary studies. In clinical trials of mold active prophylactic agents conducted in HSCT the incidence of IMI ranges from 1.3% to 5%. [5] [6] [7] In the neutropenic phase of allo-HSCT, micafungin prophylaxis was effective in preventing invasive fungal infections. these studies. However, the selected time points for analysis of the incidence of IMI were shorter than in our study, suggesting that with longer follow-up the reported incidences in these trials would have been higher. Noteworthy, our population seemed at a higher risk for developing IMI than the patients included in the aforementioned studies, not only by the well-described bias in enrolling patients into clinical trials, 18 but also because our patients were older and had received more immunosuppressive transplant strategies (eg CD34+ selection and cord blood transplantation) than those included in the clinical trials.
The large number of patients included in this study allowed subgroup analyses in patients with various diseases and receiving different transplant approaches. We observed a trend toward a relatively higher incidence of IMI in patients with ALL when compared with other diseases. This non-statistical significant trend could be explained by the prolonged corticosteroid exposure during ALL therapy and by a less well-established anti-mold prophylactic strategy in patients with this disease in the induction/consolidation phase as opposed to AML and MDS. However, other transplant-related factors as the incidence of GVHD (not addressed in this study) could also play a role in the incidence of IMI in this population. Contrary to other studies, we did not observe a higher incidence of IMI in patients receiving more immunosuppressive transplant modalities such as CD34+ selection or cord blood. 19 While it is possible that the more aggressive prophylactic approach used at our center may overcome a higher risk for mold infections in patients receiving highly immunosuppressive transplant modalities, this would need to be confirmed in comparative studies. 
22,23
Mortality after IMI was high in our patients, consistent with prior reports, 8, 24 especially for those with Mucorales, reflecting the aggressiveness of these infections even in the prophylactic era and indicating the need for continuing improvement in this field despite the low prevalence of IMI.
Our study has several limitations. The goal of the study was to evaluate the effectiveness of a standardized approach. Since the actual prophylaxis of individual patients was not examined we do not report rates of compliance, toxicity or use of alternative approaches for individual patients. Work up for IMI was done by institutional standards and at the discretion of the clinician, thus there could be greater variability than in controlled clinical trials. Acknowledging these limitations, our study nevertheless provides real world experience on the efficacy of mold active prophylaxis in a large heterogeneous, high risk cohort with contemporary transplant practices and supportive care.
In conclusion, our anti-mold prophylactic strategy consisting of micafungin bridged to voriconazole resulted in a very low incidence of IMI in recipients of allo-HSCT, although mortality in patients developing IMI remains high.
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